Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
03 January 2018 - 11:00PM
Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company
developing and commercializing novel antibiotics to treat serious
bacterial infections, today announced that Dan Wechsler, President
and Chief Executive Officer, will be presenting at the 36th Annual
J.P. Morgan Healthcare Conference that is being held in San
Francisco, CA from January 8-11, 2018. Melinta’s presentation will
take place on Wednesday, January 10, 2018 at 10:30am Pacific Time.
Mr. Wechsler will present an overview of the Company’s strategy
following its November 2017 merger with Cempra and November 2017
agreement to acquire The Medicines Company’s infectious disease
business (currently projected to close early in Q1).
A webcast of the presentation can be accessed on the investor
page of Melinta’s website at http://ir.melinta.com/events. A replay
of the webcast will also be archived on Melinta’s website following
the conference.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is dedicated to saving lives threatened
by the global public health crisis of bacterial infections, through
the development and commercialization of novel antibiotics that
provide new and better therapeutic solutions. Melinta’s lead
product is Baxdela, an antibiotic approved by the U.S. FDA for use
in the treatment of acute bacterial skin and skin structure
infections (ABSSSI). Melinta also has an extensive pipeline of
preclinical and clinical stage products representing many important
classes of antibiotics, each targeted at a different segment of the
anti-infective market. Together, this pipeline provides
Melinta with the unique ability to provide providers and patients
with a range of solutions that can meet the tremendous need for
novel antibiotics treating serious infections. Visit
www.melinta.com for more information.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this communication constitute
“forward-looking statements” within the meaning of Section 27A of
the Securities Act and Section 21E of the Securities Exchange Act
and are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act and Section 21E of the Securities Exchange
Act and are making this statement for purposes of complying with
those safe harbor provisions. These forward-looking statements
reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control.
Risks and uncertainties for Melinta include, but are not limited
to: inability to complete its proposed transactions, acquiring the
capital stock of certain subsidiaries of The Medicines Company and
certain other assets related to The Medicines Company’s infectious
disease business unit; liquidity and trading market for shares
prior to and following the consummation of the proposed
transactions; costs and potential litigation associated with the
proposed transactions; failure or delay in obtaining required
approvals by governmental or quasi-governmental entity necessary to
consummate the proposed transactions; failure to satisfy other
conditions to the closing of the proposed transactions; risks
related to the costs, timing and regulatory review of the Company’s
studies and clinical trials, including its ability to address the
issues identified by the FDA in the complete response letter
relating to Melinta’s new drug applications for solithromycin for
community acquired bacterial pneumonia; uncertainties in obtaining
successful clinical results for product candidates and unexpected
costs that may result therefrom; inability or the delay in
obtaining required regulatory approvals for product candidates,
which may result in unexpected cost expenditures; failure to
realize any value of certain product candidates developed and being
developed, in light of inherent risks and difficulties involved in
successfully bringing product candidates to market; inability to
develop new product candidates and support existing products;
inability to commercialize and launch any product candidate that
receives regulatory approval, including Baxdela; the Company’s
anticipated capital expenditures, its estimates regarding its
capital requirements and its need for future capital; uncertainties
of cash flows and inability to meet working capital needs; cost
reductions that may not result in anticipated level of cost savings
or cost reductions prior to or after the consummation of the
proposed transactions; the approval by the FDA and EMA and any
other similar foreign regulatory authorities of other competing or
superior products brought to market; risks resulting from
unforeseen side effects; risk that the market for the Company’s
products may not be as large as expected; inability to obtain,
maintain and enforce patents and other intellectual property rights
or the unexpected costs associated with such enforcement or
litigation; inability to obtain and maintain commercial
manufacturing arrangements with third party manufacturers or
establish commercial scale manufacturing capabilities; loss of or
diminished demand from one or more key customers or distributors;
unexpected cost increases and pricing pressures; the possibility of
economic recession and its negative impact on customers, vendors or
suppliers; and risks associated with the possible failure to
realize certain benefits of the proposed transactions, including
future financial, tax, accounting treatment, and operating results.
Many of these factors that will determine actual results are beyond
Melinta’s ability to control or predict.
Other risks and uncertainties are more fully described in our
Annual Report on Form 10-K for the year ended December 31, 2016, as
amended by Form 10-K/A, filed with the SEC on April 13, 2017, and
in other filings that Melinta makes and will make with the SEC.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. The statements made in this press release speak
only as of the date stated herein, and subsequent events and
developments may cause our expectations and beliefs to change.
While we may elect to update these forward-looking statements
publicly at some point in the future, we specifically disclaim any
obligation to do so, whether as a result of new information, future
events or otherwise, except as required by law. These
forward-looking statements should not be relied upon as
representing our views as of any date after the date stated
herein.
No Offer or Solicitation:
This press release is being provided for informational purposes
only and does not constitute (i) an offer to purchase, nor a
solicitation of an offer to sell, subscribe for or buy any
securities, (ii) an offer to exchange any securities or (iii) the
solicitation of any vote for approval of any transaction. There
shall not be any offer, solicitation, sale or exchange of any
securities in any state or other jurisdiction in which such offer,
solicitation, sale, or exchange is not permitted.
For More Information:
Media Inquiries:Amra Maynard(917)
302-2702Amra.maynard@inventivhealth.com
Investor Inquiries:Raj Mistry(312)
801-2051 rmistry@melinta.com
Lisa DeFrancescoldefrancesco@melinta.com
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Apr 2024 to May 2024
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From May 2023 to May 2024